Christoph Driessen
- Molecular Biology top 2%
- Oncology top 1%
- Immunology top 2%
- Hematology top 0.5%
- Cancer Research top 2%
- Co-authors
- Marianne KrausHerman S. OverkleeftHubert KalbacherHidde L. PloeghLothar RinkMichael ReichHarold A. ChapmanGuo‐Ping Shi
- Topics
- Multiple Myeloma Research and Treatments (50 papers)Ubiquitin and proteasome pathways (39 papers)Peptidase Inhibition and Analysis (28 papers)
- Cited by
- HematologyImmunologyOncology
- Journals
- Proceedings of the National Academy of SciencesAngewandte Chemie International EditionJournal of Clinical Investigation
- Partner nations
- SwitzerlandGermanyNetherlands
In The Last Decade
Christoph Driessen
131 papers receiving 5.7k citations
Hit Papers
Peers
Comparison fields: 5 of 117
- Molecular Biology 2.9k
- Oncology 1.7k
- Immunology 1.5k
- Hematology 1.4k
- Cancer Research 687
Countries citing papers authored by Christoph Driessen
This map shows the geographic impact of Christoph Driessen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Driessen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Driessen more than expected).
Fields of papers citing papers by Christoph Driessen
This network shows the impact of papers produced by Christoph Driessen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Driessen. The network helps show where Christoph Driessen may publish in the future.
Co-authorship network of co-authors of Christoph Driessen
This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Driessen. A scholar is included among the top collaborators of Christoph Driessen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Driessen. Christoph Driessen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 2 | |
| 3 | 5 | |
| 4 | 3 | |
| 5 | 2 | |
| 6 | 14 | |
| 7 | 13 | |
| 8 | 35 | |
| 9 | 28 | |
| 10 | 1 | |
| 11 | 11 | |
| 12 | MULTIPLE MYELOMA MANAGEMENT: OUTCOMES IN REAL-WORLD PRACTICE | 1 |
| 13 | MULTIPLE MYELOMA MANAGEMENT: PRACTICE PATTERNS ACROSS EUROPE | 3 |
| 14 | 329 | |
| 15 | 23 | |
| 16 | 31 | |
| 17 | Autophagy promotes MHC class II presentation of peptides from intracellular source proteinsbreakdown → | 504 |
| 18 | 41 | |
| 19 | 63 | |
| 20 | 104 |
About Christoph Driessen
Christoph Driessen is a scholar working on Hematology, Oncology and Genetics, having authored 144 papers that have together received 5.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (50 papers), Ubiquitin and proteasome pathways (39 papers) and Peptidase Inhibition and Analysis (28 papers). The work is most often cited by research in Hematology (1.4k citations), Immunology (1.5k citations) and Oncology (1.7k citations). Christoph Driessen has collaborated with scholars based in Switzerland, Germany and Netherlands. Frequent co-authors include Marianne Kraus, Herman S. Overkleeft, Hubert Kalbacher, Hidde L. Ploegh, Lothar Rink, Michael Reich, Harold A. Chapman, Guo‐Ping Shi, Ana‐Maria Lennon‐Duménil and Ekkehard Weber. Their work appears in journals such as Proceedings of the National Academy of Sciences, Angewandte Chemie International Edition and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.